Carol Gallagher, Pharm.D., is an experienced independent director with over 30 years of biopharma experience. From 1989 through 2011, she held roles of increasing responsibility in commercial, drug development, and business development in both large and small biopharma companies including Eli Lilly, Amgen, Pfizer and IDEC Pharmaceuticals. Her last operational role was CEO of Calistoga Pharmaceuticals which was acquired by Gilead in 2011. From 2014 through 2023, she held Partner and Advisor roles in biopharma venture capital investing at New Enterprise Associates. She currently serves as an independent director on the boards of both private and public biopharma companies.
Carol studied chemistry at Vanderbilt University and then pursued a clinical background, attaining Bachelor of Science and Doctor of Pharmacy degrees from the College of Pharmacy at the University of Kentucky.